SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/21/24 Processa Pharmaceuticals, Inc. 8-K:7,9 2/20/24 11:7.2M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 36K 2: EX-99.1 Miscellaneous Exhibit HTML 13K 6: R1 Cover HTML 47K 8: XML IDEA XML File -- Filing Summary XML 12K 11: XML XBRL Instance -- form8-k_htm XML 16K 7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 97K Document -- pcsa-20240220_lab 5: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 64K Linkbase Document -- pcsa-20240220_pre 3: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 12K pcsa-20240220 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 35K 10: ZIP XBRL Zipped Folder -- 0001493152-24-007444-xbrl Zip 16K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): i February 20, 2024
Commission file number i 001-39531
i PROCESSA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
i Delaware | i 45-1539785 | |
(State
or Other Jurisdiction of Incorporation or Organization) |
(I.R.S.
Employer Identification Number) |
i 7380 Coca Cola Drive, i Suite 106, i Hanover, i Maryland i 21076
(Address of Principal Executive Offices, Including Zip Code)
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
i Common stock: Par value $.0001 | i PCSA | i Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation Disclosure.
Mr. George Ng, CEO for Processa Pharmaceuticals, Inc. (“Processa”) presented at the Winter Wrap-Up MicroCap Rodeo Conference on February 20, 2024.
Processa’s presentation is furnished as Exhibit 99.1 and will also be made available in the “Investors” section on Processa’s website, located at https://www.processapharmaceuticals.com.
Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the “Investors” section of Processa’s website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit | Description | |
99.1 | Processa Pharmaceuticals Presentation dated February 20, 2024 | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on February 21, 2024.
PROCESSA PHARMACEUTICALS, INC. | ||
Registrant | ||
By: | /s/ George Ng | |
George Ng | ||
Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/21/24 | None on these Dates | ||
For Period end: | 2/20/24 | |||
List all Filings |